Overview Phase III Study of ASP2151 in Herpes Simplex Patients Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex. Phase: Phase 3 Details Lead Sponsor: Maruho Co., Ltd.